StockData
Madrigal Pharmaceuticals, Inc. logo

Madrigal Pharmaceuticals, Inc. (MDGL) stock

MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/304% above fair value
$421.99−1.97 (-0.46%)

Close on Nov 17, 2026Market cap $9.75BP/E –Yield –

Madrigal Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

Madrigal Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $490.14M, up 154.4% year over year. For fiscal 2025 it was $388.53M, up 64.1% from the year before. Over ten years it grew 66.1% a year on average. The highest annual figure on record is $388.53M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$388.53M+64.1%
FY2024Dec 31, 2024$236.72M-13.1%
FY2023Dec 31, 2023$272.35M+11.0%
FY2022Dec 31, 2022$245.44M+19.6%
FY2021Dec 31, 2021$205.16M+11.0%
FY2020Dec 31, 2020$184.81M+155.5%
FY2019Dec 31, 2019$72.32M+184.9%
FY2018Dec 31, 2018$25.39M+4.1%
FY2017Dec 31, 2017$24.39M+53.1%
FY2016Dec 31, 2016$15.93M+556.4%
FY2015Dec 31, 2015$2.43M-96.4%
FY2014Dec 31, 2014$68.21M-5.1%
FY2013Dec 31, 2013$71.86M+45.4%
FY2012Dec 31, 2012$49.41M+19.2%
FY2011Dec 31, 2011$41.46M+3.0%
FY2010Dec 31, 2010$40.25M-21.2%
FY2009Dec 31, 2009$51.05M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$91.18M+68.6%
Q1 FY2026Mar 31, 2026$108.69M+146.1%
Q4 FY2025Dec 31, 2025$116.27M+353.3%
Q3 FY2025Sep 30, 2025$174.00M+153.1%
Q2 FY2025Jun 30, 2025$54.08M-23.9%
Q1 FY2025Mar 31, 2025$44.17M-38.0%
Q4 FY2024Dec 31, 2024$25.65M-63.7%
Q3 FY2024Sep 30, 2024$68.74M-3.1%
Q2 FY2024Jun 30, 2024$71.09M+3.6%
Q1 FY2024Mar 31, 2024$71.24M+14.6%
Q4 FY2023Dec 31, 2023$70.64M-0.1%
Q3 FY2023Sep 30, 2023$70.95M+3.9%
Q2 FY2023Jun 30, 2023$68.61M+17.3%
Q1 FY2023Mar 31, 2023$62.15M+29.7%
Q4 FY2022Dec 31, 2022$70.74M+33.8%
Q3 FY2022Sep 30, 2022$68.27M+24.4%
Q2 FY2022Jun 30, 2022$58.50M+13.3%
Q1 FY2022Mar 31, 2022$47.93M+4.7%
Q4 FY2021Dec 31, 2021$52.89M-1.0%
Q3 FY2021Sep 30, 2021$54.87M+3.0%
Q2 FY2021Jun 30, 2021$51.63M+15.5%
Q1 FY2021Mar 31, 2021$45.77M+37.0%
Q4 FY2020Dec 31, 2020$53.43M+114.5%
Q3 FY2020Sep 30, 2020$53.29M+174.0%
Q2 FY2020Jun 30, 2020$44.69M+186.6%
Q1 FY2020Mar 31, 2020$33.40M+169.9%
Q4 FY2019Dec 31, 2019$24.91M+180.8%
Q3 FY2019Sep 30, 2019$19.45M+213.1%
Q2 FY2019Jun 30, 2019$15.59M+205.2%
Q1 FY2019Mar 31, 2019$12.37M+138.0%
Q4 FY2018Dec 31, 2018$8.87M+36.2%
Q3 FY2018Sep 30, 2018$6.21M-7.0%
Q2 FY2018Jun 30, 2018$5.11M-25.0%
Q1 FY2018Mar 31, 2018$5.20M+18.7%
Q4 FY2017Dec 31, 2017$6.51M+17.9%
Q3 FY2017Sep 30, 2017$6.68M-14.4%
Q2 FY2017Jun 30, 2017$6.82M–
Q1 FY2017Mar 31, 2017$4.38M–
Q4 FY2016Dec 31, 2016$5.52M–
Q3 FY2016Sep 30, 2016$7.81M–

More Madrigal Pharmaceuticals figures

See a number that looks wrong?